The company has gained a lot of attention since launching an AI-enabled personal health app last month.
Shares of Tempus AI, Inc. were volatile Tuesday, surging to highs last seen in mid-November before paring gains to trade slightly higher.
Trading volume was nearly double the daily average as the healthcare tech firm confirmed it will report fourth-quarter and full-year 2024 earnings on Feb. 24, with a conference call at 4:30 p.m. ET.
Wall Street expects the company to report an adjusted loss of $0.16 per share on revenue of $203.12 million.
Retail sentiment on Stocktwits remained ‘bullish,’ though the score read slightly lower than last week following insider selling.
CEO and Chairman Eric Lefkofsky recently sold nearly 240,000 shares between Feb. 5-7, netting over $16.2 million, while CFO Jim Rogers sold 8,712 shares for $588,669, as per SEC filings.
Stocktwits users had mixed reactions. One trader noted the stock “gave back most of the pump,” suggesting weak holding interest amid short pressure.
Another pointed to a bullish technical setup, predicting a move toward $80.
Tempus AI has gained a lot of attention since launching an AI-enabled personal health app last month.
But it also made headlines after former House Speaker Nancy Pelosi purchased 50 call options in the stock, a trade closely watched by retail investors.
Last week, the company announced the completion of its $600 million acquisition of Ambry Genetics.
TD Cowen reportedly believes the acquisition strengthens Tempus with a $300-million profitable lab, enhances product offerings, and accelerates its path to positive free cash flow.
The research firm, however, thinks Ambry’s slower growth is a concern.
Tempus AI stock has surged over 70% since its June 2024 IPO, with its Stocktwits following up nearly 700% in three months.
Short interest has also climbed from 3.9% at the start of 2025 to 7.3% by the end of January, per Koyfin data.
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
